RGO Stock Financial Analysis - Regeneron Pharmaceuticals, Inc. (DB) Stock

Overview

Regeneron Pharmaceuticals, Inc. is an American biotechnology company primarily engaged in the research, development, and commercialization of pharmaceutical products for the treatment of serious medical conditions. Headquartered in Tarrytown, New York, Regeneron is a leader in the field of biopharmaceuticals, with a robust portfolio of products targeting oncology, cardiovascular diseases, and infectious diseases, among others. Significant projects include the development of Eylea, a treatment for macular degeneration, and Dupixent, a drug designed for asthma and dermatology treatments. Regeneron is also noted for its rapid development of REGEN-COV, a monoclonal antibody cocktail for COVID-19. The company's commitment to high scientific standards and rapid innovation continues to drive its success in biotechnology.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 14,214.20 MM.
The operating income for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 3,956.70 MM.
The net income for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 4,458.60 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	14,214.20	3,956.70	4,458.60
2025-03-31	14,085.70	3,975.30	4,499.30
2024-12-31	14,202.00	4,145.10	4,412.60
2024-09-30	13,847.10	4,128.50	4,654.50
2024-06-30	13,489.10	4,095.80	4,321.70
2024-03-31	13,100.10	4,004.20	3,857.80
2023-12-31	13,117.20	4,233.20	3,953.60
2023-09-30	13,097.30	4,407.10	3,991.10
2023-06-30	12,670.80	4,419.80	4,299.00
2023-03-31	12,369.90	4,710.20	4,182.70
2022-12-31	12,172.90	4,994.00	4,338.40
2022-09-30	13,710.20	6,504.90	5,370.30
2022-06-30	14,226.80	7,128.40	5,686.80
2022-03-31	16,508.10	9,168.70	7,933.60
2021-12-31	16,071.70	8,994.80	8,075.30
2021-09-30	13,542.90	7,474.10	6,995.50
2021-06-30	12,384.10	6,680.00	6,205.40
2021-03-31	9,197.60	3,989.20	4,003.80
2020-12-31	8,497.10	3,664.60	3,513.20
2020-09-30	7,937.70	3,120.50	3,156.00
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31	40.90	38.34
2024-09-30	43.26	40.43
2024-06-30	40.31	37.77
2024-03-31	36.10	33.85
2023-12-31	37.05	34.77
2023-09-30	37.37	35.06
2023-06-30	40.20	37.82
2023-03-31	39.03	36.77
2022-12-31	40.51	38.22
2022-09-30	50.20	47.39
2022-06-30	53.27	50.03
2022-03-31	74.81	70.30
2021-12-31	76.40	71.97
2021-09-30	66.31	62.53
2021-06-30	58.90	55.38
2021-03-31	37.59	35.13
2020-12-31	32.65	30.52
2020-09-30	29.08	27.29
2020-06-30	27.25	25.83
2020-03-31	20.83	19.91

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 4,743.50 MM.
The cash from investing activities for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is -670.30 MM.
The cash from financing activities for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is -3,986.90 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	4,743.50	-670.30	-3,986.90
2025-03-31	3,953.10	-133.50	-3,336.80
2024-12-31	4,420.50	-2,468.10	-2,200.50
2024-09-30	4,247.40	-2,884.90	-1,511.10
2024-06-30	4,070.50	-2,806.80	-1,284.40
2024-03-31	4,738.90	-4,636.50	-1,420.50
2023-12-31	4,594.00	-3,185.10	-1,790.10
2023-09-30	5,224.20	-4,976.60	-1,591.60
2023-06-30	4,738.80	-4,288.00	-1,909.30
2023-03-31	4,280.80	-2,315.00	-1,396.20
2022-12-31	5,014.90	-3,784.60	-1,009.00
2022-09-30	5,667.50	-3,939.60	-1,668.00
2022-06-30	8,452.20	-6,570.70	-557.60
2022-03-31	8,514.50	-6,031.00	-574.70
2021-12-31	7,081.30	-5,384.70	-1,005.80
2021-09-30	5,939.80	-3,677.00	-404.50
2021-06-30	2,271.90	-2,014.00	-177.90
2021-03-31	2,588.60	-686.40	-2,672.50
2020-12-31	2,618.10	-70.60	-1,970.50
2020-09-30	2,174.50	25.70	-2,010.90
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Management Effectiveness

The roa for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 0.12.
The roe for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 0.16.
The roic for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 0.14.
The croic for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 0.02.
The ocroic for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 0.12.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	0.12	0.16	0.14	0.02	0.12
2025-03-31	0.13	0.17	0.14	-0.01	0.14
2024-12-31	0.14	0.17	0.15	-0.00	0.13
2024-09-30	0.13	0.19	0.14	-0.00	0.13
2024-06-30	0.13	0.16	0.13	-0.04	0.16
2024-03-31	0.14	0.17	0.14	-0.01	0.16
2023-12-31	0.14	0.19	0.14	-0.05	0.19
2023-09-30	0.16	0.21	0.16	-0.05	0.18
2023-06-30	0.15	0.21	0.16	-0.05	0.18
2023-03-31	0.16	0.22	0.16	0.02	0.16
2022-12-31	0.23	0.31	0.22	0.00	0.23
2022-09-30	0.24	0.31	0.22	0.00	0.23
2022-06-30	0.37	0.38	0.24	0.05	0.35
2022-03-31	0.45	0.66	0.34	0.08	0.36
2021-12-31	0.41	0.73	0.36	0.03	0.30
2021-09-30	0.43	0.69	0.35	0.09	0.13
2021-06-30	0.43	0.69	0.33	0.00	0.12
2021-03-31	0.25	0.33	0.26	-0.05	0.17
2020-12-31	0.24	0.32	0.23	0.04	0.17
2020-09-30	0.23	0.30	0.22	0.01	0.15
2020-06-30	0.23	0.31	0.26	0.08	0.26
2020-03-31	0.18	0.24	0.18	0.04	0.17

Gross Margins

The gross margin for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 0.49.
The net margin for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 0.32.
The operating margin for Regeneron Pharmaceuticals, Inc. as of 30 June 2025 is 0.28.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.49	0.32	0.28
2025-03-31	0.50	0.31	0.30
2024-12-31	0.51	0.34	0.29
2024-09-30	0.53	0.32	0.30
2024-06-30	0.51	0.29	0.30
2024-03-31	0.53	0.30	0.33
2023-12-31	0.53	0.30	0.34
2023-09-30	0.54	0.34	0.35
2023-06-30	0.56	0.34	0.35
2023-03-31	0.58	0.34	0.38
2022-12-31	0.61	0.39	0.47
2022-09-30	0.63	0.39	0.47
2022-06-30	0.66	0.40	0.50
2022-03-31	0.67	0.48	0.55
2021-12-31	0.65	0.50	0.56
2021-09-30	0.63	0.52	0.54
2021-06-30	0.63	0.51	0.52
2021-03-31	0.54	0.44	0.41
2020-12-31	0.54	0.41	0.42
2020-09-30	0.55	0.34	0.34
2020-06-30	0.62	0.34	0.32
2020-03-31	0.52	0.27	0.30

MX:REGN
IT:1REGN	490,80 €
AT:REGN
GB:0R2M
US:REGN	573,38 US$
PE:REGN